B56-PP2A的小分子调节器恢复了4E-BP功能,以抑制癌细胞中eIF4E依赖的翻译
Michelle A Lum1,2, Kayla A Jonas1,2, Shreya Parmar1,2
1Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska, USA.
The Journal of clinical investigation
|January 27, 2025
概括
PP2A的小分子激活剂 (SMAPs) 通过激活4E-BP1.1来恢复瘤的翻译控制. 这种方法显示了癌症治疗的潜力,并克服了对现有治疗方法的耐药性.
科学领域:
- 分子生物学分子生物学
- 癌症研究 癌症研究
- 生物化学 生物化学
背景情况:
- 失调的真核细胞启动因子4E (eIF4E) 依存的翻译驱动瘤发生和治疗耐药性.
- eIF4E结合蛋白 (4E-BPs) 是eIF4E翻译的关键负调节者,在癌症中经常被禁用.
- 蛋白酸酶2A (PP2A) 已与4E-BP1调节有关.
研究的目的:
- 研究B56-PP2A酸酶在调节4E-BP蛋白中的作用.
- 探索激活B56-PP2A的治疗潜力,以恢复瘤中的转化控制.
- 在癌症模型中评估小分子PP2A激活剂 (SMAPs) 的疗效.
主要方法:
- 用偏向小分子激活剂 (SMAPs) 治疗PP2A.
- 对4E-BP1/2酸化和转录调节的分析.
- 封顶结合试验,共免疫沉和封顶依赖转化试验.
- 评估已有的癌症疗法的亡和强化.
主要成果:
- SMAP治疗诱导了4E-BP1/2的PP2A依赖的低酸化,将B56-PP2As识别为4E-BP酸酶.
- SMAPs通过B56-PP2A→TFE3/TFEB→ATF4信号轴触发了4E-BP1的转录上调.
- B56-PP2A激活抑制了eIF4F复合组合和上限依赖的翻译.
- SMAPs促进了瘤细胞中的4E-BP1依赖性亡,并增强了ERK或mTOR抑制剂的疗效.
结论:
- B56-PP2A激活策划了一个瘤抑制程序,涉及4E-BP1转录诱导和激活.
- 小型癌症治疗方案 (SMAP) 显示出作为一种新的癌症治疗策略的潜力.
- PP2A激活剂可能提供一种方法来克服针对eIF4E依赖转化治疗的耐药性.
相关概念视频
01:23Negative Regulator Molecules
35.1K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.1K
02:23Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:33Initiation of Translation
30.4K
Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
30.4K
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K